Idealpharma
ActiveSummary
The computed 12-month bankruptcy probability of Idealpharma is 1.8% (moderate). The annual accounts of Idealpharma for financial year 2025 show a net loss of 78% of the equity at the start of that year. The 2025 annual accounts show equity of €55,469 and a net result of -€193,427. Equity is growing by about 3.8% per year across the filed financial years. Its solvency ranks better than 18% of 12,650 sector peers (NACE 47, financial year 2025). The company has been active since 2004 and the Belgian Official Gazette contains no insolvency or warning signals.
History
Acts, filings and financial milestones
18-09
Gazette deed
Resignation: Erik Van Nuffel (director)3 facts ▸
- General meeting, 30-07-2024
- Director resignation, Erik Van Nuffel (director)
- Other provision, director discharge, 30-07-2024
Show earlier events
About the unread acts
Of the 5 Belgian Official Gazette deeds we know for this company, 1 has been read. The other 4 have not been read yet: what they contain is neither established nor disproved here.